secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091744
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics posts Q2 net loss of $13.4M; announces ProGen partnership for oral obesity drug RT-114
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities totaled $30.9M as of June 30, 2024, down from $48.5M at Dec. 31, 2023.
- Net loss of $13.4M for Q2 2024, compared to $18.7M in same period 2023; includes $4.1M stock-based compensation.
- R&D expenses fell to $6.1M from $11.1M YoY, driven by workforce reduction and timing of preclinical/clinical studies.
- Announced co-development partnership with ProGen for RT-114, an oral GLP-1/GLP-2 dual agonist, with 50/50 cost and revenue share.
- Phase 1 study for RT-114 expected to start in 2025; completed $10.0M equity offering in July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017024091744/0000950170-24-091744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017024091744/rani-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer